Skip to main content
. 2015 Jul 15;10(7):e0131864. doi: 10.1371/journal.pone.0131864

Table 1. Number of patients according to the course of treatment.

Course of treatment Infliximab Etanercept Adalimumab Total
1st TNF-α inhibitor 108 (40.1%) 95 (35.3%) 66 (24.5%) 269
Switching 38 (54.2%) 26 (37.1%) 6 (8.5%) 70
2nd TNF-α inhibitor 13 (18.5%) 12 (17.1%) 45 (64.2%) 70

TNF, tumor necrosis factor.